Results 11 to 20 of about 21,980 (135)
Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy. [PDF]
ABSTRACT Chimeric antigen receptor T cell (CAR‐T) therapy has demonstrated remarkable efficacy in haematologic malignancies but remains constrained in solid tumours due to limited tumour penetration, immunosuppressive microenvironments and the risk of cytokine release syndrome (CRS).
Yang R +10 more
europepmc +2 more sources
Regulation and Mechanism of Deleted in Breast Cancer-1 on Dendritic Cell Function in Systemic Lupus Erythematosus. [PDF]
LPS‐stimulated DC activation upregulated DBC1. DBC1‐deficient DC ameliorated murine SLE symptoms. DBC1 deficiency suppressed immune responses in DC. DBC1 deficiency lowered STAT5 expression and subsequent phosphorylation. STAT5 overexpression abolished murine SLE remission primed by DBC1 deficiency.
Xiao ZX +9 more
europepmc +2 more sources
Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence [PDF]
B7-H1 binding to programmed death-1 may deliver a coinhibitory signal to T cells that is involved in the regulation of T-cell activation and tolerance. B7-H1 plays a key role in dysfunction of dendritic cells (DCs) during chronic HBV infection, but the expression mechanism of B7-H1 remains unclear.
Man, Li +8 more
openaire +2 more sources
Lower lip squamous cell carcinomas (LLSCC) could be associated with a previous history of potentially malignant oral diseases (PMOD), especially actinic cheilitis (AC), with high sun exposure being a well-described risk factor. Immune evasion mechanisms,
Vinícius Gonçalves de Souza +7 more
doaj +1 more source
The application of chimeric antigen receptor (CAR)-T cell therapy in patients with advanced solid tumors remains a significant challenge. Simultaneously targeting antigen and the solid tumor microenvironment are two major factors that greatly impact CAR ...
Baozhu Huang +8 more
doaj +1 more source
Targeting the PD-1/PD-L1 Axis in Human Vitiligo
Autoreactive CD8+ T cells play a pivotal role in melanocyte destruction in autoimmune vitiligo. Immunotherapy for melanoma often leads to autoimmune side-effects, among which vitiligo-like depigmentation, indicating that targeting immune checkpoints can ...
Marcella Willemsen +3 more
doaj +1 more source
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core +2 more sources
Clinical trials of immunotherapy in mantle cell lymphoma have not yet delivered desirable results, partly because of the inhibitory machinery of the tumor and its microenvironment.
Lijuan Wang +14 more
doaj +1 more source
CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [PDF]
The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80 and CD86 was evaluated at mRNA level in 94 patients affected ...
Antonelli, Alessandro +15 more
core +3 more sources
Immunohistochemical Expression of Programmed Death Ligand-1 in Tumour Milieu of Oral Cancer
Objectives: To determine the immunohistochemical expression of PD-L1 in oral squamous cell carcinoma and to correlate it with clinicopathological parameters.
Moomal Aslam Khan +3 more
doaj +1 more source

